Roundup Lawsuit Settlements: The $10.9 Billion Bayer Deal

Roundup is the world’s most widely used herbicide, with its active ingredient glyphosate applied to farms, gardens, and public spaces in over 160 countries. Monsanto developed Roundup in 1974 and paired it with “Roundup Ready” genetically modified crops starting in the 1990s.

The litigation centers on claims that glyphosate causes non-Hodgkin lymphoma (NHL), a group of blood cancers. In 2015, the International Agency for Research on Cancer (IARC), a division of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” (Group 2A). Monsanto (and later Bayer) has consistently disputed this classification, citing regulatory approvals from the EPA, EFSA, and other agencies.

Bayer acquired Monsanto for $63 billion in 2018 — just months before the first Roundup trial resulted in a $289 million verdict against the company. The acquisition is widely regarded as one of the worst corporate deals in modern history due to the unanticipated litigation costs.

The $10.9 billion settlement is divided into tiers based on the type and severity of cancer diagnosis, duration of Roundup exposure, and supporting medical evidence. The settlement covers claims filed through the cutoff date and includes provisions for future claims.

Why Payouts Seem Low

Many claimants express frustration that individual payouts from a $10.9 billion fund are in the five- to low-six-figure range. The math is straightforward: $10.9 billion divided by 100,000+ claimants yields an average of roughly $100,000 before legal fees. After attorney fees of 33-40%, the effective per-claimant average drops to approximately $60,000-$67,000.

This is a common pattern in mass tort settlements. The headline number sounds enormous, but when divided among tens of thousands of claimants, individual recoveries are modest compared to what a successful individual trial might yield.

While the majority of the $10.9 billion settlement has been distributed, Roundup litigation is not fully resolved. Key developments as of 2026:

• New cases continue: Despite the settlement, new plaintiffs continue to file Roundup lawsuits, particularly those diagnosed with NHL after the settlement cutoff date.
• Bayer’s total cost: The company has spent over $16 billion on Roundup litigation when including legal fees, settlements, and reserves — far exceeding initial estimates.
• EPA re-review: A federal court ordered the EPA to reassess its finding that glyphosate is not likely carcinogenic. The outcome could impact future litigation.
• Label warnings: Bayer has proposed adding cancer warnings to Roundup labels as part of future litigation risk mitigation, though this remains disputed.